SM
NKTR icon

SG3 Management’s Nektar Therapeutics NKTR Stock Holding History

SG3 Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-733
Closed -$35.2K – 292
2022
Q3 		$35.2K Sell
733
-6,974
-90% -$415K ﹤0.01% 253
2022
Q2 		$439K Sell
7,707
-14,100
-65% -$890K 0.05% 219
2022
Q1 		$1.76M Buy
21,807
+20,407
+1,458% +$3.02M 0.05% 325
2021
Q4 		$284K Buy
1,400
+133
+10% +$28.9K 0.01% 751
2021
Q3 		$341K Buy
+1,267
New +$305K 0.01% 680
2021
Q2 		– Sell
-4,333
Closed -$1.3M – 1229
2021
Q1 		$1.3M Buy
4,333
+1,833
+73% +$571K 0.03% 528
2020
Q4 		$638K Buy
2,500
+500
+25% +$129K 0.01% 675
2020
Q3 		$498K Buy
+2,000
New +$629K 0.02% 571

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SG3 Management's NKTR Position: Q2 2022 in Review

SG3 Management sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 5,667 shares — an estimated $358K sold.

SG3 Management first reported a position in NKTR in Q3 2020 and held it in 4 quarters. The position peaked at $468K in Q4 2020. 227 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

  • SG3 Management reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 5,667 Nektar Therapeutics shares in Q2 2022, an estimated $358K.
  • SG3 Management first reported a position in Nektar Therapeutics in Q3 2020 and held it in 4 quarters.
  • SG3 Management's Nektar Therapeutics position peaked at $468K in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.